Ovid and Take­da cre­ate a one-team strat­e­gy to steer a neu­ro drug to the world

Je­re­my Levin’s team at Ovid Ther­a­peu­tics has been scour­ing the globe for new drugs to treat or­phan brain dis­eases. And af­ter spend­ing a year in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.